Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Debt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBITDA Margin (2019 - 2025)

Pulmonx (LUNG) has disclosed EBITDA Margin for 7 consecutive years, with 66.76% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin fell 14.0% to 66.76% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 62.24% through Sep 2025, up 903.0% year-over-year, with the annual reading at 67.93% for FY2024, 1911.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 66.76% at Pulmonx, down from 61.78% in the prior quarter.
  • The five-year high for EBITDA Margin was 57.21% in Q4 2024, with the low at 149.25% in Q1 2022.
  • Average EBITDA Margin over 5 years is 88.67%, with a median of 84.4% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 21958bps in 2021, while the deepest fall reached -5843bps in 2021.
  • Over 5 years, EBITDA Margin stood at 93.65% in 2021, then increased by 2bps to 91.44% in 2022, then rose by 25bps to 68.43% in 2023, then grew by 16bps to 57.21% in 2024, then decreased by -17bps to 66.76% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 66.76%, 61.78%, and 63.71% for Q3 2025, Q2 2025, and Q1 2025 respectively.